Last reviewed · How we verify
Acelex (POLMACOXIB)
At a glance
| Generic name | POLMACOXIB |
|---|---|
| Sponsor | CrystalGenomics |
| Target | Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Osteoarthritis
Common side effects
Key clinical trials
- Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear. (NA)
- Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649 (PHASE1)
- Phase III Study of CG100649 in Osteoarthritis Patients (PHASE3)
- Study of CG100649 Versus Celecoxib in Osteoarthritis Patients (PHASE2)
- Drug-Drug Interaction Study of "CG-651" in Healthy Volunteer (PHASE1)
- Drug-Drug Interaction Study of "CG100650" in Healthy Volunteers (PHASE1)
- Phase I Study on Multiple Oral Dosing of CG100649 (PHASE1)
- Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acelex CI brief — competitive landscape report
- Acelex updates RSS · CI watch RSS
- CrystalGenomics portfolio CI